NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO

NEOGENOMICS INC

Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).
Adjusted EBITDA negative $16M vs positive $5M in Q2 2021; adjusted net loss $20M vs $1M.
Chris Smith appointed CEO effective Aug 15; Vishal Sikri named President, Pharma Services in May.
Cash and securities $466M; company launched enterprise-wide performance improvement plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.